May 2, 2018 / 5:36 AM / 3 months ago

BRIEF-Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform

May 2 (Reuters) - ASIT BIOTECH SA:

* ANNOUNCES VALIDATION OF ITS PATIENT BLOOD CELL IN VITRO SELECTION PLATFORM FOR ITS NEW PRODUCT CANDIDATES AND FILING OF A EUROPEAN PATENT APPLICATION

* DURING A FIRST PHASE III TRIAL DURING A FIRST PHASE III TRIAL (BTT009) CLINICAL EFFICACY OF GP-ASIT+ WAS STATISTICALLY SIGNIFICANTLY CONFIRMED

* EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAI EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAINED ON GROUP OF PATIENTS TREATED AT GHENT UNIVERSITY HOSPITAL

* SELECTION METHOD DEVELOPED BY ASIT BIOTECH HAS BEEN CLAIMED IN A PATENT APPLICATION FILED IN EUROPE ON 30 APRIL 2018

* PATENT SAFEGUARDS ASIT BIOTECH’S FUTURE DEVELOPMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below